Vanzacaftor / tezacaftor / deutivacaftor tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Alyftrek
- Company
- Vertex Pharmaceuticals Incorporated
- Medicine type
- Chemical medicine
- Therapeutic area
- Respiratory & allergy
- Indications recorded in the public source
- US: Cystic fibrosis in patients aged 6 years or older with a clinical diagnosis and at least one CFTR variant that is responsive on clinical/in-vitro evidence or produces CFTR protein. Confirm the genotype using an FDA-cleared genetic test if it is unknown.
- Indication source and scope
- US prescribing information revised March 2026. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- China availability status
- Chinese approval, locally approved indications and current availability have not been independently verified in this import.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218730s001lbl.pdf
- Alyftrek — official prescribing information
Official prescribing information · US prescribing information revised March 2026
English primary source reviewed. This evidence describes the cited overseas jurisdiction and does not verify Chinese approval, indications, reimbursement or market availability.
Evidence reviewed:
Open the interactive record, public price references and discussions